Darifenacin's Effectiveness In OAB Wet Patients As Measured By Dry Days

Main Category: Urology / Nephrology
Article Date: 27 Oct 2008 - 2:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:not yet rated

Healthcare Prof:not yet rated


PHILADELPHIA, PA, USA (UroToday.com) - This analysis set forth to determine the onset and number of consecutive dry days and reductions of UI episodes (IEs) provided by darifenacin, using pooled data from 3 phase III studies (multicenter, randomized, double-blind, placebo-controlled 12-week studies with darifenacin of fixed-doses of 7.5 and 15 mg once daily).

Each study was preceded by a screening visit, 2-week washout (if required) and a 2 week treatment-free or placebo run-in period. Patients were then randomized to 12 weeks' double-blind treatment with study medication. Subjects included men and women ≥18 years of age with symptoms of OAB for ≥6 months; 5-50 IEs per week (incontinence) during the run-in period; an average of ≥8 micturitions per 24 hours; and ≥1 urgency episode per 24 hours. Efficacy was determined from electronic daily diaries used to record OAB symptoms, including IEs. Incontinence data were used to determine the proportion of patients achieving ≥3 consecutive dry days and reductions in IEs. A dry day was defined as not having an IE recorded during a 24-hour period. IE responses were grouped into three categories: reductions of >3, >5 and >10 IEs/week from baseline. Darifenacin 7.5 and 15 mg treatment was well tolerated and effective. In both darifenacin dose groups, more patients achieved ≥3 consecutive dry days compared with placebo. Onset of improvement, as indicated by significant changes from placebo, was seen within 2 weeks of darifenacin treatment and sustained over time (12-week observation period).

As symptom bother has been related to UI, increases in the number of dry days may be more clinically relevant for OAB patients with UI than other study endpoints, such as reductions in urgency or micturitions.

Presented by D. Newman, W. S. Aronstein, Y. Seifu, A. Peters-Larson, and L. Mongay at the 39th Annual Conference of the Society of Urologic Nurses and Associates - October 3 - 6, 2008 - Philadelphia, PA, USA

Reported by UroToday.com Contributing Editor Diane K. Newman, MSN, CRNP, FAAN, BCIA-PMDB

UroToday - the only urology website with original content written by global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday.com

Copyright © 2008 - UroToday

Article adapted by Medical News Today from original press release.
Visit our urology / nephrology section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Urotoday. "Darifenacin's Effectiveness In OAB Wet Patients As Measured By Dry Days." Medical News Today. MediLexicon, Intl., 27 Oct. 2008. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/126905.php>

APA
Urotoday. (2008, October 27). "Darifenacin's Effectiveness In OAB Wet Patients As Measured By Dry Days." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/126905.php.

Please note: If no author information is provided, the source is cited instead.


Urology / Nephrology

Most Popular Articles



Follow Our Urology News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Urology / Nephrology Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »